Stocks and InvestingStocks and Investing
Tue, March 1, 2022
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022

Tiago Fauth Maintained (ABCL) at Buy with Increased Target to $40 on, Feb 25th, 2022


Published on 2024-10-27 19:50:57 - WOPRAI, Tiago Fauth
  Print publication without navigation


Tiago Fauth of Credit Suisse, Maintained "AbCellera Biologics Inc." (ABCL) at Buy with Increased Target from $39 to $40 on, Feb 25th, 2022.

Tiago has made no other calls on ABCL in the last 4 months.



There are 2 other peers that have a rating on ABCL. Out of the 2 peers that are also analyzing ABCL, 0 agree with Tiago's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Tiago


  • Robert Wasserman of "Benchmark" Initiated at Strong Buy and Held Target at $27 on, Tuesday, December 21st, 2021
  • Do Kim of "Piper Sandler" Initiated at Buy and Held Target at $33 on, Friday, November 19th, 2021